Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold, WTI
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold, WTI
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold, Agronomics,
The Times: Shares in Close Brothers, Lloyds, Barclays and Investec will be in sharp focus this morning after the Financial Conduct Authority (FCA) published details of a proposed redress scheme following the car loan mis-selling scandal.
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold,
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Gold, Pound/Dollar, Blencowe,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, Avacta, Audioboom,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, African Pioneer,
Ananda Developments (AQSE: ANA), a company focused on becoming a leading provider of CBD-based medicines for chronic inflammatory pain conditions, recently presented to life science industry leaders at the 10th LSX
CleanTech Lithium (CTL), an exploration and development company, advancing sustainable lithium projects in Chile, announced the results of a recently completed Scoping Study for the Francisco Basin Project, which confirmed the
Poolbeg Pharma (POLB), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announced its unaudited interim results for the six months to 30 June 2023.